No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d2iw6B1, 1.0000, 0.00, 1.000, 134, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2, d1oiyB1, 0.9978, 0.20, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3, d1oi9B1, 0.9978, 0.20, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
4, d4eomB1, 0.9976, 0.21, 1.000, 134, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
5, d1h27B1, 0.9976, 0.21, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
6, d1h1rB1, 0.9976, 0.21, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
7, d4eolB1, 0.9975, 0.22, 1.000, 134, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
8, d4eoqB1, 0.9972, 0.23, 1.000, 134, 134, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
9, d4cfmB1, 0.9972, 0.23, 1.000, 135, 134, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
10, d3ddqB1, 0.9972, 0.23, 0.993, 139, 134, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
11, d1h1sB1, 0.9972, 0.23, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
12, d4eojB1, 0.9971, 0.24, 1.000, 134, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
13, d4cfwD1, 0.9971, 0.23, 1.000, 134, 134, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
14, d4cfwB1, 0.9971, 0.23, 1.000, 135, 134, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
15, d1qmzD1, 0.9970, 0.24, 1.000, 135, 134, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
16, d1p5eB1, 0.9970, 0.24, 1.000, 135, 134, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
17, d5cyiB1, 0.9969, 0.24, 1.000, 135, 134, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
18, d1qmzB1, 0.9969, 0.24, 1.000, 135, 134, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
19, d5lmkB1, 0.9968, 0.24, 1.000, 135, 134, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
20, d4eorB1, 0.9968, 0.25, 1.000, 134, 134, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
21, d1h26B1, 0.9968, 0.24, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
22, d4eopB1, 0.9967, 0.25, 1.000, 134, 134, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
23, d4eonD1, 0.9967, 0.25, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
24, d3dogB1, 0.9966, 0.26, 0.993, 139, 134, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
25, d1h26D1, 0.9965, 0.25, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
26, d4i3zD1, 0.9964, 0.26, 0.970, 135, 134, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
27, d2uzlD1, 0.9964, 0.26, 1.000, 134, 134, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
28, d4i3zB1, 0.9963, 0.26, 0.970, 135, 134, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
29, d2g9xB1, 0.9963, 0.27, 0.993, 138, 134, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
30, d4eooB1, 0.9962, 0.28, 0.993, 135, 134, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
31, d4cfmD1, 0.9962, 0.26, 1.000, 135, 134, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
32, d1h1qB1, 0.9962, 0.27, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
33, d1pkdB1, 0.9961, 0.28, 1.000, 135, 134, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
34, d1h25B1, 0.9961, 0.27, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
35, d4eopD1, 0.9960, 0.28, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
36, d2cjmB1, 0.9960, 0.28, 1.000, 134, 134, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
37, d1h24B1, 0.9960, 0.27, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
38, d2cjmD1, 0.9959, 0.27, 1.000, 134, 134, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
39, d2uzlB1, 0.9958, 0.29, 1.000, 134, 134, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
40, d1h1sD1, 0.9958, 0.28, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
41, d5nevB1, 0.9957, 0.29, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
42, d3ddpB1, 0.9957, 0.29, 0.993, 139, 134, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
43, d4eoiB1, 0.9956, 0.29, 0.993, 139, 134, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
44, d4eonB1, 0.9955, 0.32, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
45, d1h27D1, 0.9955, 0.29, 1.000, 134, 134, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
46, d1h1rD1, 0.9954, 0.29, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
47, d1e9hB1, 0.9954, 0.29, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
48, d4eosB1, 0.9952, 0.30, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
49, d2c5tB1, 0.9952, 0.30, 1.000, 134, 134,  
50, d4eolD1, 0.9950, 0.30, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
51, d3ddqD1, 0.9950, 0.31, 1.000, 134, 134, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
52, d2uzeD1, 0.9950, 0.31, 0.993, 139, 134, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
53, d2uueB1, 0.9950, 0.33, 1.000, 135, 134, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
54, d4eokB1, 0.9949, 0.31, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
55, d5nevD1, 0.9948, 0.32, 0.993, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
56, d3ddpD1, 0.9947, 0.31, 1.000, 135, 134, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
57, d2uzeB1, 0.9946, 0.32, 0.993, 139, 134, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
58, d1gy3D1, 0.9946, 0.35, 1.000, 135, 134, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
59, d3dogD1, 0.9945, 0.32, 1.000, 135, 134, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
60, d1oiyD1, 0.9944, 0.32, 0.993, 139, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
61, d1h1qD1, 0.9944, 0.32, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
62, d1e9hD1, 0.9944, 0.33, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
63, d5lmkD1, 0.9943, 0.32, 1.000, 135, 134, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
64, d1gy3B1, 0.9943, 0.34, 1.000, 134, 134, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
65, d4eorD1, 0.9942, 0.33, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
66, d2wpaB1, 0.9942, 0.33, 1.000, 135, 134, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
67, d2g9xD1, 0.9942, 0.35, 1.000, 135, 134, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
68, d2bpmB1, 0.9942, 0.34, 0.993, 138, 134, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
69, d2i40B1, 0.9941, 0.35, 1.000, 135, 134, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
70, d2v22B1, 0.9940, 0.34, 1.000, 135, 134, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
71, d4ii5B1, 0.9939, 0.33, 1.000, 135, 134, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
72, d1vywB1, 0.9939, 0.35, 0.955, 135, 134, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
73, d1pkdD1, 0.9939, 0.36, 1.000, 135, 134, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
74, d1jsuB1, 0.9939, 0.34, 1.000, 135, 134, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
75, d4ii5D1, 0.9938, 0.34, 1.000, 135, 134, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
76, d2uzbD1, 0.9938, 0.35, 0.955, 135, 134, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
77, d2uzbB1, 0.9938, 0.38, 1.000, 135, 134, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
78, d1fvvB1, 0.9938, 0.39, 1.000, 135, 134, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
79, d1h24D1, 0.9937, 0.34, 1.000, 137, 134, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
80, d4eosD1, 0.9936, 0.35, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
81, d2wxvB1, 0.9936, 0.35, 1.000, 135, 134, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
82, d1jstB1, 0.9936, 0.36, 1.000, 134, 134, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
83, d4eojD1, 0.9935, 0.35, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
84, d5if1D1, 0.9934, 0.36, 1.000, 134, 134, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
85, d1urcB1, 0.9934, 0.36, 1.000, 134, 134, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
86, d2wipB1, 0.9933, 0.36, 1.000, 135, 134, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
87, d2uzdD1, 0.9933, 0.38, 1.000, 135, 134, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
88, d2bkzB1, 0.9933, 0.40, 1.000, 135, 134, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
89, d2c4gB1, 0.9932, 0.39, 1.000, 134, 134, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
90, d3eidB1, 0.9931, 0.40, 1.000, 135, 134, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
91, d2wihB1, 0.9931, 0.38, 1.000, 134, 134, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
92, d2c4gD1, 0.9931, 0.38, 1.000, 134, 134, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
93, d4eokD1, 0.9930, 0.38, 0.993, 135, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
94, d4eoqD1, 0.9929, 0.37, 1.000, 134, 134, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
95, d4eomD1, 0.9929, 0.37, 1.000, 134, 134, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
96, d2c5nD1, 0.9929, 0.38, 1.000, 134, 134, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
97, d1p5eD1, 0.9929, 0.37, 0.985, 135, 134, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
98, d2wevB1, 0.9927, 0.38, 1.000, 135, 134, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
99, d1h25D1, 0.9927, 0.38, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
100, d2wevD1, 0.9926, 0.37, 1.000, 135, 134, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
101, d2c6tD1, 0.9926, 0.38, 0.985, 135, 134, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
102, d2c5tD1, 0.9926, 0.43, 1.000, 135, 134,  
103, d1finB1, 0.9926, 0.38, 0.985, 135, 134, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
104, d2uueD1, 0.9925, 0.38, 1.000, 137, 134, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
105, d2c5pB3, 0.9925, 0.39, 0.985, 135, 134,  
106, d2wxvD1, 0.9924, 0.38, 1.000, 135, 134, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
107, d2wihD1, 0.9924, 0.42, 1.000, 134, 134, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
108, d2c5nB1, 0.9924, 0.43, 1.000, 134, 134, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
109, d1h1pB1, 0.9923, 0.39, 1.000, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
110, d4fx3D1, 0.9922, 0.45, 1.000, 135, 134, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
111, d4eooD1, 0.9922, 0.40, 1.000, 135, 134, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
112, d2c5pD3, 0.9922, 0.42, 1.000, 134, 134,  
113, d1okwB1, 0.9922, 0.39, 0.985, 135, 134, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
114, d1finD1, 0.9922, 0.40, 1.000, 135, 134, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
115, d2c5vB1, 0.9921, 0.40, 1.000, 137, 134, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
116, d2c5oD1, 0.9920, 0.39, 1.000, 135, 134, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
117, d1ol2B1, 0.9920, 0.41, 0.985, 135, 134, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
118, d2wfyD1, 0.9919, 0.39, 1.000, 135, 134, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
119, d2c5xB1, 0.9919, 0.40, 0.985, 137, 134, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
120, d5if1B1, 0.9918, 0.40, 1.000, 135, 134, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
121, d2v22D1, 0.9918, 0.41, 1.000, 134, 134, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
122, d2c6tB1, 0.9918, 0.40, 0.985, 135, 134, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
123, d2c5oB1, 0.9918, 0.46, 1.000, 135, 134, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
124, d2c5vD1, 0.9917, 0.42, 1.000, 135, 134, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
125, d1okwD1, 0.9917, 0.41, 0.993, 135, 134, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
126, d1okuD3, 0.9917, 0.41, 0.985, 135, 134,  
127, d4fx3B1, 0.9916, 0.40, 1.000, 135, 134, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
128, d2c5xD1, 0.9916, 0.41, 1.000, 134, 134, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
129, d1okuB3, 0.9915, 0.40, 0.985, 135, 134,  
130, d2wfyB1, 0.9914, 0.41, 1.000, 135, 134, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
131, d1urcD1, 0.9914, 0.42, 1.000, 134, 134, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
132, d1fvvD1, 0.9914, 0.42, 0.985, 135, 134, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
133, d1ol1B1, 0.9913, 0.42, 1.000, 137, 134, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
134, d1h28B1, 0.9911, 0.41, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
135, d1ol2D1, 0.9910, 0.41, 1.000, 135, 134, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
136, d2whbD1, 0.9909, 0.42, 0.985, 135, 134, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
137, d1okvB1, 0.9909, 0.43, 0.985, 135, 134, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
138, d1h28D1, 0.9908, 0.43, 1.000, 135, 134, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
139, d1okvD1, 0.9907, 0.42, 1.000, 135, 134, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
140, d2uzdB1, 0.9902, 0.43, 0.985, 137, 134, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
141, d3tnwB1, 0.9901, 0.49, 1.000, 135, 134, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
142, d2whbB1, 0.9900, 0.21, 0.992, 133, 133, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
143, d1jstD1, 0.9900, 0.45, 0.985, 135, 134, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
144, d5cyiD1, 0.9899, 0.47, 0.993, 135, 134, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
145, d4bcnB1, 0.9899, 0.22, 1.000, 133, 133, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
146, d3bhtB1, 0.9898, 0.22, 1.000, 133, 133, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
147, d1ol1D1, 0.9898, 0.23, 0.992, 138, 133, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
148, d1oiuB1, 0.9898, 0.44, 0.985, 135, 134, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
149, d1h1pD1, 0.9897, 0.24, 1.000, 133, 133, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
150, d3bhvB1, 0.9895, 0.51, 1.000, 135, 134, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
151, d3bhuB1, 0.9895, 0.24, 0.992, 138, 133, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
152, d3my5B1, 0.9894, 0.24, 0.992, 138, 133, CDK2/CYCLINA IN COMPLEX WITH DRB
153, d4bcmB1, 0.9893, 0.25, 0.992, 138, 133, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
154, d4bcpB1, 0.9891, 0.25, 1.000, 133, 133, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
155, d1oiuD1, 0.9885, 0.26, 1.000, 133, 133, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
156, d3tnwD1, 0.9882, 0.28, 1.000, 133, 133, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
157, d4bcpD1, 0.9875, 0.29, 0.992, 133, 133, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
158, d4bcoB1, 0.9869, 0.32, 1.000, 133, 133, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
159, d3f5xB1, 0.9867, 0.36, 0.992, 134, 133, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
160, d3bhtD1, 0.9865, 0.35, 1.000, 133, 133, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
161, d3my5D1, 0.9864, 0.35, 0.992, 138, 133, CDK2/CYCLINA IN COMPLEX WITH DRB
162, d3bhuD1, 0.9862, 0.35, 0.992, 138, 133, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
163, d3bhvD1, 0.9861, 0.36, 0.992, 138, 133, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
164, d4bcmD1, 0.9858, 0.36, 0.992, 138, 133, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
165, d2iw6D1, 0.9827, 0.38, 1.000, 133, 133, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
166, d4eoiD1, 0.9824, 0.21, 1.000, 132, 132, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
167, d2iw9D1, 0.9822, 0.22, 1.000, 132, 132, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
168, d2iw8D1, 0.9822, 0.23, 1.000, 132, 132, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
169, d2iw8B1, 0.9822, 0.23, 1.000, 132, 132, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
170, d4bcnD1, 0.9821, 0.24, 1.000, 132, 132, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
171, d1oi9D1, 0.9820, 0.24, 1.000, 132, 132, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
172, d2bkzD1, 0.9818, 0.24, 1.000, 132, 132, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
173, d4bcoD1, 0.9816, 0.25, 1.000, 132, 132, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
174, d2wipD1, 0.9814, 0.25, 1.000, 132, 132, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
175, d3f5xD1, 0.9813, 0.26, 1.000, 132, 132, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
176, d1oguD1, 0.9813, 0.27, 1.000, 132, 132, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
177, d2bpmD1, 0.9810, 0.27, 1.000, 132, 132, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
178, d2i40D1, 0.9808, 0.28, 1.000, 132, 132, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
179, d1vywD1, 0.9808, 0.29, 1.000, 132, 132, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
180, d4cfnD1, 0.9802, 0.28, 1.000, 132, 132, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
181, d3eidD1, 0.9791, 0.32, 1.000, 132, 132, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
182, d2iw9B1, 0.9784, 0.34, 1.000, 132, 132, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
183, d4cfnB1, 0.9750, 0.43, 1.000, 132, 132, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
184, d2wpaD1, 0.9731, 0.22, 1.000, 131, 131, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
185, d4bckB1, 0.9708, 0.29, 1.000, 131, 131, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
186, d4bcqB1, 0.9690, 0.65, 1.000, 133, 133, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
187, d1oguB1, 0.9678, 0.68, 1.000, 133, 133, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
188, d4bcqD1, 0.9662, 0.21, 1.000, 130, 130, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
189, d4bckD1, 0.9566, 0.73, 1.000, 133, 133, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
190, p4cfuB2, 0.9535, 0.64, 1.000, 131, 131, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
191, d2cchB1, 0.9532, 0.18, 0.992, 129, 128, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
192, d2cchD1, 0.9528, 0.19, 1.000, 128, 128, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
193, d2cciB1, 0.9514, 0.22, 1.000, 128, 128, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
194, d3ej1B1, 0.9505, 0.27, 1.000, 128, 128, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
195, d2cciD1, 0.9503, 0.30, 1.000, 128, 128, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
196, d3ej1D1, 0.9496, 0.31, 1.000, 128, 128, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
197, d1vinA1, 0.9486, 0.33, 1.000, 128, 128, BOVINE CYCLIN A3
198, p4cfvB2, 0.9462, 0.36, 0.992, 128, 128, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
199, p3qhwB2, 0.9455, 0.17, 1.000, 128, 127, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
200, p3qhwD2, 0.9454, 0.21, 0.976, 128, 127, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
201, p3qhrB2, 0.9440, 0.21, 0.976, 128, 127, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
202, p4cfuD2, 0.9438, 0.27, 0.976, 128, 127, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
203, p3qhrD2, 0.9438, 0.28, 0.992, 128, 127, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
204, p4cfvD2, 0.9430, 0.28, 0.976, 128, 127, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
205, d1w98B2, 0.9302, 0.31, 1.000, 128, 127, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
206, d5l2wB1, 0.9252, 1.20, 0.341, 140, 132, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
207, p5lqeB2, 0.9228, 1.20, 0.341, 140, 132, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
208, p2wmbB2, 0.9223, 1.21, 0.348, 140, 132, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
209, p5lqeD2, 0.9221, 0.23, 1.000, 125, 124, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
210, p2x1nD2, 0.9217, 0.25, 1.000, 125, 124, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
211, p2wmbD2, 0.9215, 0.25, 1.000, 125, 124, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
212, p2x1nB2, 0.9206, 0.27, 1.000, 125, 124, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
213, p2wmaB2, 0.9206, 0.28, 1.000, 125, 124, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
214, p4cfxD2, 0.9199, 0.31, 1.000, 125, 124, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
215, p4cfxB2, 0.9198, 0.31, 1.000, 125, 124, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
216, p2wmaD2, 0.9188, 0.33, 1.000, 125, 124, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
217, p2w96A2, 0.9183, 0.34, 1.000, 125, 124, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
218, d1g3nC1, 0.9147, 0.37, 1.000, 125, 124, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
219, d1g3nG1, 0.9143, 0.79, 0.378, 129, 127, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
220, p3eocB2, 0.9138, 0.79, 0.378, 129, 127, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
221, p3eocD2, 0.9130, 1.26, 0.252, 132, 131, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
222, p2jgzB2, 0.8929, 1.26, 0.252, 132, 131, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
223, p5hq0B2, 0.8916, 1.26, 0.252, 132, 131, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
224, p4y72B2, 0.8916, 0.29, 1.000, 124, 123, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
225, p5lqfE2, 0.8905, 0.32, 1.000, 124, 123, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
226, p4yc3B2, 0.8898, 0.77, 0.447, 124, 123, CDK1/CYCLINB1/CKS2 APO
227, p5lqfB2, 0.8893, 0.80, 0.447, 124, 123, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
228, p2w99A2, 0.8749, 0.80, 0.447, 124, 123, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
229, p2w9zA2, 0.8741, 0.82, 0.447, 126, 123, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
230, d2f2cA1, 0.8709, 0.82, 0.447, 126, 123, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
231, d4tthA1, 0.8708, 0.83, 0.447, 124, 123, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
232, d4p41A3, 0.8708, 0.84, 0.447, 124, 123,  
233, d2eufA1, 0.8693, 0.79, 0.397, 123, 121, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
234, d1jowA1, 0.8615, 0.80, 0.397, 123, 121, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
235, d1f5qB1, 0.8591, 1.61, 0.233, 138, 129, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
236, d1f5qD1, 0.8568, 1.60, 0.233, 138, 129, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
237, d1xo2A1, 0.8564, 1.60, 0.233, 138, 129, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
238, p2w9fA2, 0.8553, 1.62, 0.233, 138, 129, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
239, d1bu2A1, 0.8319, 1.62, 0.233, 138, 129, X-RAY STRUCTURE OF A VIRAL CYCLIN FROM HERPESVIRUS SAIMIRI
240, p3g33D2, 0.8234, 1.69, 0.233, 137, 129, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
241, p3g33B2, 0.8234, 2.36, 0.205, 141, 132, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
242, p2b9rB2, 0.8185, 2.04, 0.192, 142, 130, CRYSTAL STRUCTURE OF HUMAN CYCLIN B1
243, p2b9rA2, 0.8175, 2.04, 0.192, 142, 130, CRYSTAL STRUCTURE OF HUMAN CYCLIN B1
244, p5ceiB_, 0.8002, 1.78, 0.233, 137, 129, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
245, p5icpB_, 0.7997, 0.76, 0.398, 119, 118, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
246, p5i5zB_, 0.7986, 1.87, 0.228, 127, 127, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
247, p5hbeB_, 0.7984, 0.82, 0.377, 115, 114, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
248, p5hbhB_, 0.7980, 0.82, 0.377, 115, 114, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
249, p4g6lB_, 0.7971, 0.77, 0.460, 113, 113, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
250, p4f7jB_, 0.7969, 0.79, 0.460, 113, 113, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
251, p5hnbB_, 0.7966, 2.60, 0.171, 268, 129, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
252, p4crlB_, 0.7965, 2.45, 0.172, 267, 128, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
253, p4f7sB_, 0.7960, 2.53, 0.172, 266, 128, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
254, p5bnjB_, 0.7954, 2.48, 0.164, 266, 128, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
255, p5fgkB_, 0.7953, 2.61, 0.163, 270, 129, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
256, p4f6uB_, 0.7939, 2.61, 0.163, 270, 129, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
257, p5hvyB_, 0.7937, 2.56, 0.172, 267, 128, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
258, p5idpB_, 0.7935, 2.81, 0.168, 268, 131, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
259, p5idnB_, 0.7935, 2.50, 0.164, 266, 128, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
260, p3rgfB_, 0.7935, 2.48, 0.164, 266, 128, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC
261, p4f6wB_, 0.7930, 2.49, 0.172, 267, 128, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
262, p4f7lB_, 0.7929, 2.52, 0.164, 266, 128, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 2 (TERT- BUTYL [3-({[3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5- YL]CARBAMOYL}AMINO)PROPYL]CARBAMATE)
263, p4f6sB_, 0.7929, 2.49, 0.164, 266, 128, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
264, p5hbjB_, 0.7923, 2.63, 0.171, 267, 129, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
265, p4f70B_, 0.7919, 2.64, 0.171, 267, 129, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 4 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[2-(MORPHOLIN-4-YL) ETHYL]UREA)
266, p4f7nB_, 0.7907, 2.63, 0.171, 268, 129, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
267, p5xs2B_, 0.7859, 2.51, 0.164, 267, 128, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
268, p5xqxB_, 0.7858, 2.47, 0.172, 266, 128, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
269, p6b3eB1, 0.7585, 2.63, 0.171, 267, 129, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
270, d5efqD1, 0.7533, 2.50, 0.164, 266, 128, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
271, p6b3eD1, 0.7519, 2.56, 0.164, 266, 128, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
272, d5efqB1, 0.7511, 2.49, 0.172, 267, 128, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
273, d4un0B1, 0.7508, 2.49, 0.172, 266, 128, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
274, d4cjyB1, 0.7507, 2.65, 0.171, 268, 129,  
275, d4nstD1, 0.7505, 2.55, 0.165, 263, 127, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
276, d2i53A1, 0.7501, 2.56, 0.165, 263, 127, CRYSTAL STRUCTURE OF CYCLIN K
277, d5acbA1, 0.7498, 2.30, 0.210, 140, 119, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
278, d5acbB1, 0.7496, 2.13, 0.214, 137, 117, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
279, d4nstB1, 0.7491, 2.18, 0.214, 137, 117, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
280, d4un0A1, 0.7485, 2.16, 0.214, 137, 117, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
281, d4cjyA1, 0.7485, 2.23, 0.205, 136, 117,  
282, d2ivxA1, 0.7483, 2.23, 0.205, 136, 117, CRYSTAL STRUCTURE OF HUMAN CYCLIN T2 AT 1.8 A RESOLUTION (CASP TARGET)
283, d4cxaB1, 0.7468, 2.34, 0.203, 137, 118, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
284, d3blhB2, 0.7445, 2.29, 0.205, 144, 117, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
285, d3tn8B1, 0.7433, 2.29, 0.205, 144, 117, CDK9/CYCLIN T IN COMPLEX WITH CAN508
286, d3my1B1, 0.7430, 2.18, 0.214, 138, 117, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
287, d4imyF1, 0.7426, 2.18, 0.214, 138, 117, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
288, d4imyB1, 0.7425, 2.35, 0.203, 138, 118, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
289, d4bchB1, 0.7425, 2.26, 0.205, 136, 117, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
290, d4cxaD1, 0.7424, 2.26, 0.205, 136, 117, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
291, d4imyD1, 0.7421, 2.42, 0.169, 143, 118, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
292, d4bciB1, 0.7416, 2.39, 0.203, 138, 118, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
293, d3blqB2, 0.7414, 2.76, 0.208, 146, 120, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
294, d3mi9B1, 0.7410, 2.76, 0.208, 146, 120, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
295, d3lq5B1, 0.7410, 2.58, 0.202, 143, 119, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
296, d4bcfB1, 0.7409, 2.55, 0.202, 143, 119, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
297, p3tniB1, 0.7409, 2.63, 0.202, 143, 119, STRUCTURE OF CDK9/CYCLIN T F241L
298, d2ivxB1, 0.7405, 2.63, 0.202, 143, 119, CRYSTAL STRUCTURE OF HUMAN CYCLIN T2 AT 1.8 A RESOLUTION (CASP TARGET)
299, p3tnhB1, 0.7404, 2.62, 0.202, 143, 119, CDK9/CYCLIN T IN COMPLEX WITH CAN508
300, d3blrB2, 0.7404, 2.39, 0.205, 136, 117, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
301, d4bcjB1, 0.7403, 2.58, 0.202, 144, 119, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
302, d4bcgB1, 0.7401, 2.62, 0.202, 143, 119, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
303, d4ogrB1, 0.7400, 2.57, 0.203, 142, 118, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
304, d3miaB1, 0.7399, 2.53, 0.212, 144, 118, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
305, p4ec9B1, 0.7397, 2.54, 0.203, 142, 118, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
306, d2pk2D2, 0.7393, 2.66, 0.202, 143, 119, CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
307, d4ogrF1, 0.7388, 2.61, 0.202, 143, 119, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
308, d2pk2C2, 0.7386, 2.44, 0.171, 141, 117, CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
309, d4or5G1, 0.7378, 2.51, 0.203, 142, 118, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
310, d4or5B1, 0.7374, 2.49, 0.203, 142, 118, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
311, d4ogrK1, 0.7369, 2.58, 0.202, 143, 119, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
312, d2pk2B2, 0.7355, 2.65, 0.202, 143, 119, CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
313, d2pk2A2, 0.7342, 2.72, 0.200, 144, 120, CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
314, p4ec8B2, 0.7114, 2.55, 0.212, 144, 118, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
315, p5l1zB2, 0.7099, 2.53, 0.203, 142, 118, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
316, p2w2hA2, 0.7067, 2.46, 0.212, 143, 118, STRUCTURAL BASIS OF TRANSCRIPTION ACTIVATION BY THE CYCLIN T1-TAT-TAR RNA COMPLEX FROM EIAV
317, p2w2hB2, 0.7064, 2.68, 0.200, 144, 120, STRUCTURAL BASIS OF TRANSCRIPTION ACTIVATION BY THE CYCLIN T1-TAT-TAR RNA COMPLEX FROM EIAV
318, d1kxuA1, 0.7012, 2.45, 0.210, 143, 119, CYCLIN H A POSITIVE REGULATORY SUBUNIT OF CDK ACTIVATING KINASE
319, d1jkwA1, 0.6951, 2.60, 0.202, 144, 119, STRUCTURE OF CYCLIN MCS2
320, d1ad6A_, 0.6604, 2.61, 0.202, 144, 119, DOMAIN A OF HUMAN RETINOBLASTOMA TUMOR SUPPRESSOR
321, p4yosA1, 0.6587, 2.71, 0.200, 144, 120, P107 POCKET DOMAIN COMPLEXED WITH LIN52 PEPTIDE
322, d4yozA1, 0.6584, 2.40, 0.229, 143, 118, P107 POCKET DOMAIN IN COMPLEX WITH HPV E7 PEPTIDE
323, d1n4mA1, 0.6579, 2.49, 0.220, 143, 118, STRUCTURE OF RB TUMOR SUPPRESSOR BOUND TO THE TRANSACTIVATION DOMAIN OF E2F-2
324, d1gh6B1, 0.6578, 2.42, 0.216, 131, 111, RETINOBLASTOMA POCKET COMPLEXED WITH SV40 LARGE T ANTIGEN
325, p4yooA1, 0.6572, 2.42, 0.216, 131, 111, P107 POCKET DOMAIN IN COMPLEX WITH LIN52 P29A PEPTIDE
326, d1o9kG_, 0.6561, 2.54, 0.225, 131, 111, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
327, d1o9kE_, 0.6555, 2.55, 0.225, 131, 111, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
328, d1o9kC_, 0.6550, 2.88, 0.178, 151, 118, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
329, d1o9kA_, 0.6543, 2.81, 0.179, 151, 117, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
330, d1n4mB1, 0.6521, 2.81, 0.179, 151, 117, STRUCTURE OF RB TUMOR SUPPRESSOR BOUND TO THE TRANSACTIVATION DOMAIN OF E2F-2
331, p4eljA3, 0.6498, 3.36, 0.091, 185, 121, CRYSTAL STRUCTURE OF THE INACTIVE RETINOBLASTOMA PROTEIN PHOSPHORYLATED AT T373
332, d3pomB1, 0.6482, 3.41, 0.075, 188, 120, CRYSTAL STRUCTURE OF THE UNLIGANDED RETINOBLASTOMA PROTEIN POCKET DOMAIN
333, d2r7gC1, 0.6466, 3.06, 0.085, 204, 117, STRUCTURE OF THE RETINOBLASTOMA PROTEIN POCKET DOMAIN IN COMPLEX WITH ADENOVIRUS E1A CR1 DOMAIN
334, d2r7gA1, 0.6452, 3.06, 0.085, 204, 117, STRUCTURE OF THE RETINOBLASTOMA PROTEIN POCKET DOMAIN IN COMPLEX WITH ADENOVIRUS E1A CR1 DOMAIN
335, d4yozA2, 0.6398, 3.08, 0.095, 202, 116, P107 POCKET DOMAIN IN COMPLEX WITH HPV E7 PEPTIDE
336, p4yooA2, 0.6386, 2.95, 0.095, 198, 116, P107 POCKET DOMAIN IN COMPLEX WITH LIN52 P29A PEPTIDE
337, d1guxB_, 0.6383, 3.05, 0.085, 188, 117, RB POCKET BOUND TO E7 LXCXE MOTIF
338, p4ellA1, 0.6357, 3.20, 0.092, 194, 119, STRUCTURE OF THE INACTIVE RETINOBLASTOMA PROTEIN POCKET DOMAIN
339, d1d3uB1, 0.6355, 3.22, 0.092, 194, 119, TATA-BINDING PROTEIN/TRANSCRIPTION FACTOR (II)B/BRE+TATA- BOX COMPLEX FROM PYROCOCCUS WOESEI
340, p4yosA2, 0.6340, 3.08, 0.094, 194, 117, P107 POCKET DOMAIN COMPLEXED WITH LIN52 PEPTIDE
341, d3pomB2, 0.6331, 2.98, 0.095, 194, 116, CRYSTAL STRUCTURE OF THE UNLIGANDED RETINOBLASTOMA PROTEIN POCKET DOMAIN
342, p5iy6M3, 0.6329, 3.10, 0.095, 195, 116, HUMAN HOLO-PIC IN THE CLOSED STATE
343, d2r7gC2, 0.6329, 3.16, 0.093, 206, 118, STRUCTURE OF THE RETINOBLASTOMA PROTEIN POCKET DOMAIN IN COMPLEX WITH ADENOVIRUS E1A CR1 DOMAIN
344, d1o9kD_, 0.6328, 3.11, 0.095, 190, 116, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
345, d1o9kF_, 0.6325, 3.02, 0.095, 194, 116, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
346, p5iyaM2, 0.6324, 3.03, 0.095, 193, 116, HUMAN CORE-PIC IN THE CLOSED STATE
347, d1n4mA2, 0.6313, 2.85, 0.093, 136, 107, STRUCTURE OF RB TUMOR SUPPRESSOR BOUND TO THE TRANSACTIVATION DOMAIN OF E2F-2
348, d3pomA2, 0.6307, 2.82, 0.074, 155, 108, CRYSTAL STRUCTURE OF THE UNLIGANDED RETINOBLASTOMA PROTEIN POCKET DOMAIN
349, d1o9kB_, 0.6305, 2.82, 0.074, 155, 108, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
350, d2r7gA2, 0.6300, 2.86, 0.121, 141, 107, STRUCTURE OF THE RETINOBLASTOMA PROTEIN POCKET DOMAIN IN COMPLEX WITH ADENOVIRUS E1A CR1 DOMAIN
351, d1o9kH_, 0.6297, 3.04, 0.097, 202, 113, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE
352, d1n4mB2, 0.6287, 2.34, 0.141, 106, 99, STRUCTURE OF RB TUMOR SUPPRESSOR BOUND TO THE TRANSACTIVATION DOMAIN OF E2F-2
353, d1gh6B2, 0.6256, 2.34, 0.141, 106, 99, RETINOBLASTOMA POCKET COMPLEXED WITH SV40 LARGE T ANTIGEN
354, p5wh1D1, 0.6254, 2.92, 0.083, 152, 109, APO FORM OF THE C-TERMINAL REGION OF HUMAN TRANSCRIPTION FACTOR IIB
355, p5n9gA1, 0.6252, 2.87, 0.121, 142, 107, TFIIIB -TBP/BRF2/DNA AND SANT DOMAIN OF BDP1-
356, p5wh1C1, 0.6244, 2.23, 0.143, 102, 98, APO FORM OF THE C-TERMINAL REGION OF HUMAN TRANSCRIPTION FACTOR IIB
357, p5n9gF1, 0.6237, 2.87, 0.121, 143, 107, TFIIIB -TBP/BRF2/DNA AND SANT DOMAIN OF BDP1-
358, d1c9bI1, 0.6237, 2.94, 0.121, 144, 107, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
359, d1c9bQ1, 0.6236, 2.95, 0.121, 144, 107, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
360, d1c9bA1, 0.6232, 2.28, 0.143, 102, 98, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
361, d1c9bM1, 0.6228, 2.75, 0.123, 143, 106, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
362, d1c9bE1, 0.6224, 2.88, 0.121, 144, 107, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
363, p4rocA1, 0.6209, 2.96, 0.121, 144, 107, HUMAN TFIIB-RELATED FACTOR 2 (BRF2) AND TBP BOUND TO U6#2 PROMOTER
364, p5n60Q2, 0.6205, 2.96, 0.121, 144, 107, CRYO-EM STRUCTURE OF RNA POLYMERASE I IN COMPLEX WITH RRN3 AND CORE FACTOR (ORIENTATION I)
365, p5n5zQ2, 0.6205, 2.90, 0.121, 143, 107, CRYO-EM STRUCTURE OF RNA POLYMERASE I IN COMPLEX WITH RRN3 AND CORE FACTOR (ORIENTATION II)
366, p5n5yQ2, 0.6205, 2.97, 0.121, 144, 107, CRYO-EM STRUCTURE OF RNA POLYMERASE I IN COMPLEX WITH RRN3 AND CORE FACTOR (ORIENTATION III)
367, p5n5xN1, 0.6205, 2.91, 0.121, 143, 107, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
368, p5n5xB1, 0.6205, 2.93, 0.113, 128, 106, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
369, p5n5xQ1, 0.6204, 2.16, 0.133, 104, 98, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
370, p5n5xK1, 0.6204, 1.99, 0.103, 104, 97, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
371, p5n5xH1, 0.6204, 2.18, 0.133, 104, 98, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
372, p5n5xE1, 0.6204, 2.18, 0.133, 104, 98, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
373, p5o7xQ1, 0.6203, 2.01, 0.103, 104, 97, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
374, p5o7xN1, 0.6203, 2.08, 0.156, 98, 96, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
375, p5o7xK1, 0.6203, 2.08, 0.156, 98, 96, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
376, p5o7xH1, 0.6203, 2.09, 0.146, 98, 96, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
377, p5o7xE1, 0.6203, 2.09, 0.156, 98, 96, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
378, p5o7xB1, 0.6203, 2.09, 0.146, 98, 96, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
379, p4roeA1, 0.6196, 2.02, 0.103, 104, 97, HUMAN TFIIB-RELATED FACTOR 2 (BRF2) AND TBP BOUND TO RPPH1 PROMOTER
380, p5iyaM3, 0.6190, 2.63, 0.155, 148, 103, HUMAN CORE-PIC IN THE CLOSED STATE
381, p5iy6M2, 0.6190, 2.63, 0.155, 148, 103, HUMAN HOLO-PIC IN THE CLOSED STATE
382, p4rodA1, 0.6177, 2.63, 0.155, 148, 103, HUMAN TFIIB-RELATED FACTOR 2 (BRF2) AND TBP BOUND TO TRNAU1 PROMOTER
383, p4eljA2, 0.6153, 2.63, 0.155, 148, 103, CRYSTAL STRUCTURE OF THE INACTIVE RETINOBLASTOMA PROTEIN PHOSPHORYLATED AT T373
384, d3pomA1, 0.6142, 2.63, 0.155, 148, 103, CRYSTAL STRUCTURE OF THE UNLIGANDED RETINOBLASTOMA PROTEIN POCKET DOMAIN
385, p4ellB1, 0.6141, 2.63, 0.155, 148, 103, STRUCTURE OF THE INACTIVE RETINOBLASTOMA PROTEIN POCKET DOMAIN
386, p5iycM3, 0.6137, 2.63, 0.155, 148, 103, HUMAN CORE-PIC IN THE INITIAL TRANSCRIBING STATE
387, p5iy8M3, 0.6137, 2.63, 0.155, 148, 103, HUMAN HOLO-PIC IN THE INITIAL TRANSCRIBING STATE
388, p4krcB_, 0.6133, 2.63, 0.155, 148, 103, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
389, p6f42V2, 0.6132, 2.63, 0.155, 148, 103, RNA POLYMERASE III CLOSED COMPLEX CC1.
390, p4krdB_, 0.6112, 2.64, 0.155, 148, 103, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
391, d1aisB1, 0.6106, 2.64, 0.155, 148, 103, TATA-BINDING PROTEIN/TRANSCRIPTION FACTOR (II)B/TATA-BOX COMPLEX FROM PYROCOCCUS WOESEI
392, p5wh1A1, 0.6103, 2.64, 0.155, 148, 103, APO FORM OF THE C-TERMINAL REGION OF HUMAN TRANSCRIPTION FACTOR IIB
393, p5wh1B1, 0.6101, 2.64, 0.155, 148, 103, APO FORM OF THE C-TERMINAL REGION OF HUMAN TRANSCRIPTION FACTOR IIB
394, p5iydM3, 0.6100, 2.64, 0.155, 148, 103, HUMAN CORE-PIC IN THE INITIAL TRANSCRIBING STATE (NO IIS)
395, p5iy9M3, 0.6100, 2.64, 0.155, 148, 103, HUMAN HOLO-PIC IN THE INITIAL TRANSCRIBING STATE (NO IIS)
396, p6f40V2, 0.6086, 2.18, 0.112, 105, 98, RNA POLYMERASE III OPEN COMPLEX
397, d1volA1, 0.6082, 2.18, 0.112, 105, 98, TFIIB (HUMAN CORE DOMAIN)/TBP (A.THALIANA)/TATA ELEMENT TERNARY COMPLEX
398, d1d3uB2, 0.6079, 1.92, 0.128, 109, 94, TATA-BINDING PROTEIN/TRANSCRIPTION FACTOR (II)B/BRE+TATA- BOX COMPLEX FROM PYROCOCCUS WOESEI
399, p6f44V2, 0.6052, 1.92, 0.128, 109, 94, RNA POLYMERASE III CLOSED COMPLEX CC2.
400, p6f41V2, 0.6040, 1.95, 0.115, 103, 96, RNA POLYMERASE III INITIALLY TRANSCRIBING COMPLEX
401, p4eljA4, 0.6039, 2.57, 0.078, 169, 103, CRYSTAL STRUCTURE OF THE INACTIVE RETINOBLASTOMA PROTEIN PHOSPHORYLATED AT T373
402, d1aisB2, 0.6037, 2.57, 0.078, 169, 103, TATA-BINDING PROTEIN/TRANSCRIPTION FACTOR (II)B/TATA-BOX COMPLEX FROM PYROCOCCUS WOESEI
403, p5iybM2, 0.6028, 3.33, 0.069, 198, 116, HUMAN CORE-PIC IN THE OPEN STATE
404, p5iy7M2, 0.6028, 3.37, 0.078, 217, 116, HUMAN HOLO-PIC IN THE OPEN STATE
405, d1c9bE2, 0.6027, 3.37, 0.078, 217, 116, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
406, d1c9bQ2, 0.6021, 1.94, 0.151, 97, 93, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
407, d1c9bI2, 0.6020, 1.94, 0.151, 97, 93, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
408, d1c9bM2, 0.6019, 3.18, 0.145, 180, 110, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
409, p5wh1B2, 0.6015, 2.70, 0.119, 105, 101, APO FORM OF THE C-TERMINAL REGION OF HUMAN TRANSCRIPTION FACTOR IIB
410, d1c9bA2, 0.6015, 2.88, 0.148, 190, 108, CRYSTAL STRUCTURE OF A HUMAN TBP CORE DOMAIN-HUMAN TFIIB CORE DOMAIN COMPLEX BOUND TO AN EXTENDED MODIFIED ADENOVIRAL MAJOR LATE PROMOTER (ADMLP)
411, p2qdjA2, 0.6014, 2.88, 0.148, 190, 108, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA PROTEIN N-DOMAIN PROVIDES INSIGHT INTO TUMOR SUPPRESSION LIGAND INTERACTION AND HOLOPROTEIN ARCHITECTURE
412, p2pk9B_, 0.6014, 1.99, 0.161, 98, 93, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
413, p2pk9D_, 0.6002, 2.14, 0.147, 96, 95, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
414, p5iydM2, 0.6001, 2.26, 0.135, 99, 96, HUMAN CORE-PIC IN THE INITIAL TRANSCRIBING STATE (NO IIS)
415, p5iy9M2, 0.6001, 1.97, 0.151, 97, 93, HUMAN HOLO-PIC IN THE INITIAL TRANSCRIBING STATE (NO IIS)
416, p5fmfP2, 0.5991, 1.97, 0.151, 97, 93, THE P-LOBE OF RNA POLYMERASE II PRE-INITIATION COMPLEX
417, p2w9fA1, 0.5991, 2.74, 0.119, 105, 101, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
418, d1volA2, 0.5991, 2.74, 0.119, 105, 101, TFIIB (HUMAN CORE DOMAIN)/TBP (A.THALIANA)/TATA ELEMENT TERNARY COMPLEX
419, p2pmiB_, 0.5987, 2.02, 0.161, 95, 93, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
420, p2pmiD_, 0.5983, 1.81, 0.154, 95, 91, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
421, p5wh1A2, 0.5977, 2.77, 0.119, 105, 101, APO FORM OF THE C-TERMINAL REGION OF HUMAN TRANSCRIPTION FACTOR IIB
422, p3h4cA1, 0.5977, 2.79, 0.119, 105, 101, STRUCTURE OF THE C-TERMINAL DOMAIN OF TRANSCRIPTION FACTOR IIB FROM TRYPANOSOMA BRUCEI
423, p5n61Q2, 0.5969, 2.48, 0.121, 118, 99, RNA POLYMERASE I INITIALLY TRANSCRIBING COMPLEX
424, p4ellB2, 0.5962, 1.81, 0.154, 95, 91, STRUCTURE OF THE INACTIVE RETINOBLASTOMA PROTEIN POCKET DOMAIN
425, p5wh1D2, 0.5933, 1.81, 0.154, 95, 91, APO FORM OF THE C-TERMINAL REGION OF HUMAN TRANSCRIPTION FACTOR IIB
426, p5iycM2, 0.5929, 1.80, 0.132, 107, 91, HUMAN CORE-PIC IN THE INITIAL TRANSCRIBING STATE
427, p5iy8M2, 0.5929, 1.80, 0.132, 107, 91, HUMAN HOLO-PIC IN THE INITIAL TRANSCRIBING STATE
428, p5wh1C2, 0.5925, 1.95, 0.129, 109, 93, APO FORM OF THE C-TERMINAL REGION OF HUMAN TRANSCRIPTION FACTOR IIB
429, p1zp2A1, 0.5919, 1.96, 0.129, 109, 93, STRUCTURE OF THE MEDIATOR SUBUNIT CYCLIN C
430, d1guxA_, 0.5913, 1.96, 0.129, 109, 93, RB POCKET BOUND TO E7 LXCXE MOTIF
431, p4v1oM2, 0.5912, 1.96, 0.129, 109, 93, ARCHITECTURE OF THE RNA POLYMERASE II-MEDIATOR CORE TRANSCRIPTION INITIATION COMPLEX
432, p4v1nM2, 0.5912, 2.22, 0.128, 111, 94, ARCHITECTURE OF THE RNA POLYMERASE II-MEDIATOR CORE TRANSCRIPTION INITIATION COMPLEX
433, p5iybM4, 0.5906, 2.22, 0.128, 111, 94, HUMAN CORE-PIC IN THE OPEN STATE
434, p5iy7M4, 0.5906, 1.96, 0.129, 109, 93, HUMAN HOLO-PIC IN THE OPEN STATE
435, p4ellA2, 0.5881, 2.30, 0.082, 137, 97, STRUCTURE OF THE INACTIVE RETINOBLASTOMA PROTEIN POCKET DOMAIN
436, d3blrB1, 0.5871, 3.41, 0.113, 214, 106, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
437, p6eu0Z2, 0.5870, 3.37, 0.113, 219, 106, RNA POLYMERASE III OPEN PRE-INITIATION COMPLEX (OC-PIC)
438, p4ec9B2, 0.5859, 3.37, 0.113, 219, 106, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
439, d4bcgB2, 0.5859, 1.92, 0.141, 107, 92, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
440, p3g33B1, 0.5855, 1.92, 0.141, 107, 92, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
441, d4bcfB2, 0.5849, 2.03, 0.086, 109, 93, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
442, p3tniB2, 0.5847, 2.31, 0.075, 118, 93, STRUCTURE OF CDK9/CYCLIN T F241L
443, d3blqB1, 0.5846, 2.31, 0.075, 118, 93, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
444, d4bcjB2, 0.5845, 2.03, 0.118, 109, 93, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
445, d3blhB1, 0.5843, 3.39, 0.113, 213, 106, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
446, d3lq5B2, 0.5835, 3.23, 0.114, 216, 105, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
447, p3g33D1, 0.5834, 2.20, 0.151, 110, 93, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
448, p2w9zA1, 0.5817, 2.14, 0.140, 107, 93, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
449, p5oqmM3, 0.5815, 2.14, 0.140, 107, 93, STRUCTURE OF YEAST TRANSCRIPTION PRE-INITIATION COMPLEX WITH TFIIH AND CORE MEDIATOR 
450, p5oqjM3, 0.5815, 2.75, 0.160, 129, 100, STRUCTURE OF YEAST TRANSCRIPTION PRE-INITIATION COMPLEX WITH TFIIH 
451, d3tn8B2, 0.5815, 2.44, 0.133, 132, 98, CDK9/CYCLIN T IN COMPLEX WITH CAN508
452, p5fz5M2, 0.5804, 1.85, 0.122, 106, 90, TRANSCRIPTION INITIATION COMPLEX STRUCTURES ELUCIDATE DNA OPENING (CC)
453, p5fywM2, 0.5804, 1.96, 0.132, 107, 91, TRANSCRIPTION INITIATION COMPLEX STRUCTURES ELUCIDATE DNA OPENING (OC)
454, d2pk2A1, 0.5795, 1.96, 0.132, 107, 91, CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
455, d4bchB2, 0.5794, 1.87, 0.122, 106, 90, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
456, p2w99A1, 0.5793, 1.91, 0.167, 97, 90, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
457, p3tnhB2, 0.5778, 1.91, 0.167, 97, 90, CDK9/CYCLIN T IN COMPLEX WITH CAN508
458, p4ec8B1, 0.5777, 3.25, 0.072, 177, 111, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
459, p5oqmM2, 0.5747, 1.95, 0.077, 109, 91, STRUCTURE OF YEAST TRANSCRIPTION PRE-INITIATION COMPLEX WITH TFIIH AND CORE MEDIATOR 
460, p5oqjM2, 0.5747, 1.95, 0.077, 109, 91, STRUCTURE OF YEAST TRANSCRIPTION PRE-INITIATION COMPLEX WITH TFIIH 
461, p5fz5M3, 0.5746, 1.95, 0.077, 109, 91, TRANSCRIPTION INITIATION COMPLEX STRUCTURES ELUCIDATE DNA OPENING (CC)
462, p5fywM3, 0.5746, 1.99, 0.156, 94, 90, TRANSCRIPTION INITIATION COMPLEX STRUCTURES ELUCIDATE DNA OPENING (OC)
463, d3my1B2, 0.5743, 1.99, 0.156, 94, 90, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
464, d4bciB2, 0.5741, 2.55, 0.133, 129, 98, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
465, d4p41A4, 0.5734, 2.61, 0.155, 109, 97,  
466, d2ivxA2, 0.5731, 2.49, 0.122, 102, 98, CRYSTAL STRUCTURE OF HUMAN CYCLIN T2 AT 1.8 A RESOLUTION (CASP TARGET)
467, d4tthA2, 0.5730, 2.60, 0.155, 109, 97, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
468, d2eufA2, 0.5728, 2.59, 0.155, 109, 97, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
469, d2ivxB2, 0.5724, 2.48, 0.097, 114, 93, CRYSTAL STRUCTURE OF HUMAN CYCLIN T2 AT 1.8 A RESOLUTION (CASP TARGET)
470, d1xo2A2, 0.5707, 2.48, 0.097, 114, 93, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
471, d2f2cA2, 0.5706, 2.60, 0.155, 109, 97, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
472, p2w96A1, 0.5702, 2.60, 0.155, 109, 97, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
473, d1jowA2, 0.5692, 2.61, 0.155, 109, 97, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
474, d2pk2D1, 0.5657, 2.59, 0.155, 109, 97, CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
475, d2pk2B1, 0.5639, 2.62, 0.155, 109, 97, CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
476, d1bu2A2, 0.5637, 2.63, 0.155, 109, 97, X-RAY STRUCTURE OF A VIRAL CYCLIN FROM HERPESVIRUS SAIMIRI
477, d2pk2C1, 0.5620, 2.57, 0.097, 113, 93, CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
478, d1tfbA1, 0.5618, 2.04, 0.056, 101, 89, NMR STUDIES OF HUMAN GENERAL TRANSCRIPTION FACTOR TFIIB: DYNAMICS AND INTERACTION WITH VP16 ACTIVATION DOMAIN 20 STRUCTURES
479, d1g3nG2, 0.5616, 2.31, 0.086, 95, 93, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
480, d1g3nC2, 0.5611, 2.31, 0.086, 95, 93, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
481, d3bhuD2, 0.5602, 2.65, 0.155, 109, 97, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
482, d3bhtD2, 0.5600, 2.32, 0.086, 95, 93, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
483, p5o7xQ2, 0.5599, 2.32, 0.086, 95, 93, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
484, p5o7xN2, 0.5599, 2.32, 0.086, 95, 93, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
485, p5o7xH2, 0.5599, 2.77, 0.144, 113, 97, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
486, d3bhvD2, 0.5598, 2.63, 0.155, 109, 97, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
487, p2b9rB1, 0.5598, 2.05, 0.056, 101, 89, CRYSTAL STRUCTURE OF HUMAN CYCLIN B1
488, d3bhuB2, 0.5594, 2.32, 0.149, 102, 94, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
489, d3bhtB2, 0.5594, 2.65, 0.155, 109, 97, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
490, d3ej1B2, 0.5588, 2.07, 0.088, 92, 91, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
491, d3my5B2, 0.5587, 2.07, 0.088, 92, 91, CDK2/CYCLINA IN COMPLEX WITH DRB
492, d3bhvB2, 0.5586, 2.09, 0.088, 92, 91, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
493, p5o7xE2, 0.5585, 2.09, 0.088, 92, 91, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
494, p5o7xB2, 0.5585, 2.67, 0.155, 109, 97, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
495, p5n5xE2, 0.5585, 2.67, 0.155, 109, 97, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
496, d3my5D2, 0.5585, 2.36, 0.120, 106, 92, CDK2/CYCLINA IN COMPLEX WITH DRB
497, p5o7xK2, 0.5584, 2.77, 0.144, 113, 97, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
498, p5n60Q3, 0.5584, 2.36, 0.120, 106, 92, CRYO-EM STRUCTURE OF RNA POLYMERASE I IN COMPLEX WITH RRN3 AND CORE FACTOR (ORIENTATION I)
499, p5n5zQ3, 0.5584, 2.39, 0.130, 106, 92, CRYO-EM STRUCTURE OF RNA POLYMERASE I IN COMPLEX WITH RRN3 AND CORE FACTOR (ORIENTATION II)
500, p5n5yQ3, 0.5584, 2.77, 0.144, 114, 97, CRYO-EM STRUCTURE OF RNA POLYMERASE I IN COMPLEX WITH RRN3 AND CORE FACTOR (ORIENTATION III)
501, p5n5xQ2, 0.5584, 2.77, 0.144, 114, 97, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
502, p5n5xN2, 0.5584, 2.42, 0.120, 106, 92, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
503, p5n5xK2, 0.5584, 2.41, 0.120, 106, 92, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
504, p5n5xH2, 0.5584, 1.90, 0.057, 99, 87, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
505, p5n5xB2, 0.5584, 2.41, 0.120, 106, 92, CRYSTAL STRUCTURE OF S. CEREVISIAE CORE FACTOR AT 3.2A RESOLUTION
506, d2cciD2, 0.5584, 2.41, 0.120, 106, 92, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
507, d1vinA2, 0.5580, 2.62, 0.135, 113, 96, BOVINE CYCLIN A3
508, d2cchB2, 0.5576, 2.91, 0.144, 113, 97, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
509, d3tnwB2, 0.5575, 2.42, 0.099, 102, 91, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
510, d4bcnB2, 0.5568, 2.80, 0.144, 113, 97, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
511, d4bcmB2, 0.5567, 2.58, 0.126, 97, 95, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
512, d2phgA1, 0.5567, 2.40, 0.100, 101, 90, MODEL FOR VP16 BINDING TO TFIIB
513, d4bcoB2, 0.5566, 2.41, 0.100, 101, 90, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
514, d2cchD2, 0.5566, 2.41, 0.100, 101, 90, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
515, p2b9rA1, 0.5565, 2.71, 0.128, 124, 94, CRYSTAL STRUCTURE OF HUMAN CYCLIN B1
516, d4bcnD2, 0.5563, 2.70, 0.128, 124, 94, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
517, d4bcpD2, 0.5560, 2.80, 0.097, 150, 93, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
518, d2g9xD2, 0.5557, 2.80, 0.097, 150, 93, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
519, d4ogrB2, 0.5556, 2.80, 0.097, 150, 93, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
520, d4bcpB2, 0.5555, 2.70, 0.128, 124, 94, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
521, d2cciB2, 0.5554, 2.89, 0.134, 142, 97, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
522, d4bcoD2, 0.5553, 2.89, 0.134, 142, 97, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
523, d2uzdB2, 0.5553, 2.69, 0.128, 124, 94, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
524, d1fvvB2, 0.5550, 2.69, 0.128, 124, 94, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
525, d3ddpD2, 0.5549, 2.71, 0.117, 124, 94, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
526, d2whbD2, 0.5548, 2.71, 0.128, 124, 94, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
527, d3ej1D2, 0.5547, 2.71, 0.128, 124, 94, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
528, d5if1B2, 0.5545, 2.94, 0.106, 150, 94, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
529, d4eosB2, 0.5545, 2.94, 0.106, 150, 94, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
530, d4eopB2, 0.5544, 2.94, 0.106, 150, 94, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
531, d4i3zD2, 0.5543, 2.72, 0.128, 124, 94, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
532, d3dogB2, 0.5539, 2.94, 0.106, 150, 94, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
533, d3ddqD2, 0.5539, 2.95, 0.106, 150, 94, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
534, d4i3zB2, 0.5537, 2.95, 0.106, 162, 94, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
535, d3dogD2, 0.5537, 2.95, 0.106, 162, 94, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
536, d1finB2, 0.5537, 2.95, 0.106, 150, 94, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
537, d3ddpB2, 0.5536, 2.95, 0.106, 150, 94, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
538, d2g9xB2, 0.5535, 2.95, 0.106, 150, 94, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
539, d1jsuB2, 0.5535, 2.95, 0.106, 150, 94, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
540, d4ii5D2, 0.5534, 2.94, 0.106, 150, 94, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
541, d4eoqD2, 0.5533, 2.95, 0.106, 150, 94, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
542, d4eoiD2, 0.5533, 2.73, 0.117, 124, 94, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
543, d4ii5B2, 0.5532, 2.73, 0.128, 123, 94, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
544, d4eoiB2, 0.5532, 2.85, 0.105, 124, 95, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
545, d3ddqB2, 0.5532, 2.85, 0.105, 124, 95, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
546, d1h1pB2, 0.5532, 2.70, 0.128, 124, 94, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
547, d2i40B2, 0.5529, 2.72, 0.117, 124, 94, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
548, d4eosD2, 0.5528, 2.71, 0.117, 124, 94, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
549, d2uzbD2, 0.5528, 2.61, 0.117, 97, 94, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
550, d2wihB2, 0.5527, 2.72, 0.117, 124, 94, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
551, d2uzeD2, 0.5527, 2.73, 0.117, 123, 94, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
552, d2c5nD2, 0.5527, 2.93, 0.134, 141, 97, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
553, d1ol2D2, 0.5527, 2.72, 0.117, 123, 94, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
554, d4eopD2, 0.5526, 2.72, 0.117, 124, 94, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
555, d4eooB2, 0.5526, 2.69, 0.129, 123, 93, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
556, d4eolD2, 0.5526, 2.68, 0.151, 111, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
557, d2uzlB2, 0.5526, 2.73, 0.117, 124, 94, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
558, d1vywB2, 0.5526, 2.73, 0.117, 124, 94, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
559, d4or5G2, 0.5525, 2.72, 0.117, 124, 94, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
560, d4or5B2, 0.5525, 2.83, 0.106, 123, 94, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
561, d2uzbB2, 0.5525, 2.69, 0.118, 123, 93, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
562, d2i40D2, 0.5525, 2.69, 0.129, 123, 93, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
563, d4ogrK2, 0.5524, 2.83, 0.106, 123, 94, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
564, d2c6tD2, 0.5524, 2.73, 0.117, 124, 94, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
565, d1okvD2, 0.5524, 2.69, 0.118, 123, 93, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
566, d5if1D2, 0.5523, 2.70, 0.118, 123, 93, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
567, d4eomD2, 0.5523, 2.68, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
568, d4bcqB2, 0.5522, 2.69, 0.129, 122, 93, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
569, d3eidB2, 0.5522, 2.69, 0.129, 123, 93, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
570, d2wpaB2, 0.5522, 2.71, 0.129, 123, 93, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
571, d2uzlD2, 0.5522, 2.70, 0.129, 122, 93, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
572, d4eojD2, 0.5520, 2.70, 0.129, 123, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
573, d2c6tB2, 0.5520, 2.69, 0.118, 123, 93, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
574, d2bpmB2, 0.5520, 2.71, 0.129, 123, 93, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
575, d1h24D2, 0.5520, 2.71, 0.129, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
576, d4bckB2, 0.5519, 2.83, 0.106, 123, 94, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
577, p4bbrM2, 0.5518, 2.71, 0.129, 122, 93, STRUCTURE OF RNA POLYMERASE II-TFIIB COMPLEX
578, d3mi9B2, 0.5518, 2.71, 0.118, 120, 93, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
579, d2wxvB2, 0.5518, 2.72, 0.118, 123, 93, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
580, d4fx3D2, 0.5517, 2.72, 0.129, 121, 93, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
581, d4eorD2, 0.5517, 2.69, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
582, d4cfmB2, 0.5517, 2.69, 0.129, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
583, d3eidD2, 0.5517, 2.71, 0.118, 123, 93, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
584, d2iw9D2, 0.5517, 2.71, 0.118, 122, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
585, d4ogrF2, 0.5516, 2.72, 0.118, 120, 93, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
586, d4imyF2, 0.5516, 2.72, 0.118, 123, 93, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
587, d4cfnB2, 0.5516, 2.70, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
588, d2iw9B2, 0.5516, 2.71, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
589, d2iw8B2, 0.5516, 2.71, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
590, d5lmkD2, 0.5515, 2.71, 0.118, 123, 93, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
591, d4eokB2, 0.5515, 2.72, 0.118, 120, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
592, d1p5eD2, 0.5515, 2.71, 0.118, 123, 93, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
593, d1finD2, 0.5515, 2.71, 0.118, 122, 93, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
594, d4eokD2, 0.5514, 2.70, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
595, d4cfmD2, 0.5514, 2.71, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
596, d1p5eB2, 0.5514, 2.81, 0.151, 111, 93, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
597, d1oi9B2, 0.5514, 2.78, 0.151, 112, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
598, d1h28D2, 0.5514, 2.72, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
599, d1h27D2, 0.5514, 2.71, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
600, d4eooD2, 0.5513, 2.71, 0.151, 111, 93, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
601, d2uzeB2, 0.5513, 2.72, 0.118, 123, 93, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
602, d1oguB2, 0.5513, 2.72, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
603, d4fx3B2, 0.5512, 2.71, 0.118, 123, 93, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
604, d4eomB2, 0.5512, 2.71, 0.118, 120, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
605, d2wevD2, 0.5512, 2.85, 0.117, 123, 94, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
606, d1qmzD2, 0.5512, 2.72, 0.118, 123, 93, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
607, d1okvB2, 0.5512, 2.71, 0.118, 123, 93, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
608, d1oiuD2, 0.5512, 2.71, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
609, d1h1rB2, 0.5512, 2.71, 0.118, 122, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
610, d5cyiB2, 0.5511, 2.72, 0.118, 123, 93, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
611, d4imyB2, 0.5511, 2.72, 0.118, 123, 93, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
612, d4eonD2, 0.5511, 2.72, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
613, d4eojB2, 0.5511, 2.86, 0.117, 124, 94, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
614, d2wipB2, 0.5511, 1.96, 0.082, 86, 85, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
615, d2cjmD2, 0.5511, 2.46, 0.154, 103, 91, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
616, d1h1sD2, 0.5511, 2.71, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
617, d1h1sB2, 0.5511, 2.73, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
618, d1gy3D2, 0.5511, 2.72, 0.118, 120, 93, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
619, d4cfwB2, 0.5510, 2.71, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
620, d2c5pD4, 0.5510, 2.72, 0.118, 123, 93,  
621, d1pkdD2, 0.5510, 2.73, 0.118, 123, 93, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
622, d1oiyB2, 0.5510, 2.91, 0.149, 111, 94, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
623, d1oiuB2, 0.5510, 2.87, 0.147, 106, 95, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
624, d1e9hB2, 0.5510, 2.72, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
625, d4eoqB2, 0.5509, 2.72, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
626, d4eolB2, 0.5509, 2.73, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
627, d1h1qB2, 0.5509, 2.74, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
628, d2wipD2, 0.5508, 2.72, 0.118, 123, 93, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
629, d2iw6B2, 0.5508, 2.72, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
630, d2c4gB2, 0.5508, 2.72, 0.118, 123, 93, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
631, d1h24B2, 0.5508, 2.71, 0.118, 122, 93, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
632, d5lmkB2, 0.5507, 2.71, 0.118, 123, 93, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
633, d2c5oD2, 0.5507, 2.73, 0.118, 123, 93, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
634, d2c4gD2, 0.5507, 2.72, 0.118, 123, 93, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
635, d2bkzB2, 0.5507, 2.71, 0.118, 123, 93, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
636, d1h26B2, 0.5507, 2.72, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
637, d4eorB2, 0.5506, 2.75, 0.118, 120, 93, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
638, d2c5nB2, 0.5506, 2.70, 0.118, 123, 93, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
639, d1ol2B2, 0.5506, 2.71, 0.118, 123, 93, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
640, p5lqfB1, 0.5505, 2.73, 0.118, 123, 93, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
641, d5cyiD2, 0.5504, 2.72, 0.118, 123, 93, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
642, d4imyD2, 0.5504, 2.72, 0.118, 123, 93, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
643, d2bkzD2, 0.5504, 2.72, 0.118, 123, 93, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
644, d1qmzB2, 0.5504, 2.74, 0.118, 123, 93, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
645, d3miaB2, 0.5503, 2.72, 0.118, 123, 93, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
646, d3f5xB2, 0.5503, 2.72, 0.118, 123, 93, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
647, d1jstB2, 0.5503, 2.72, 0.118, 123, 93, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
648, d1h1pD2, 0.5503, 2.91, 0.147, 107, 95, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
649, d3f5xD2, 0.5502, 2.73, 0.118, 122, 93, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
650, d2uzdD2, 0.5502, 2.72, 0.118, 123, 93, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
651, d1h1rD2, 0.5502, 2.72, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
652, d2c5tD2, 0.5501, 2.74, 0.118, 123, 93,  
653, d1pkdB2, 0.5501, 2.73, 0.118, 123, 93, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
654, d1h27B2, 0.5501, 2.74, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
655, d4bckD2, 0.5500, 2.73, 0.118, 123, 93, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
656, d2wxvD2, 0.5500, 2.72, 0.118, 123, 93, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
657, d1gy3B2, 0.5500, 2.72, 0.118, 123, 93, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
658, d1fvvD2, 0.5500, 2.74, 0.118, 123, 93, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
659, d2bpmD2, 0.5499, 2.72, 0.118, 123, 93, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
660, p4roeA2, 0.5498, 2.72, 0.118, 123, 93, HUMAN TFIIB-RELATED FACTOR 2 (BRF2) AND TBP BOUND TO RPPH1 PROMOTER
661, d2v22D2, 0.5498, 2.72, 0.118, 123, 93, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
662, d2v22B2, 0.5498, 2.72, 0.118, 123, 93, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
663, d2iw8D2, 0.5498, 2.72, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
664, d2cjmB2, 0.5498, 2.73, 0.118, 123, 93, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
665, d1oguD2, 0.5498, 2.73, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
666, d3tnwD2, 0.5497, 2.72, 0.118, 123, 93, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
667, p2wmaD1, 0.5497, 2.73, 0.118, 123, 93, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
668, d1h25B2, 0.5497, 2.73, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
669, d5nevB2, 0.5496, 2.73, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
670, p5l1zB1, 0.5496, 2.72, 0.118, 123, 93, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
671, d4cfnD2, 0.5496, 2.73, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
672, d1urcB2, 0.5496, 2.73, 0.118, 123, 93, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
673, d1ol1B2, 0.5496, 2.72, 0.118, 123, 93, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
674, p4rodA2, 0.5495, 2.74, 0.118, 123, 93, HUMAN TFIIB-RELATED FACTOR 2 (BRF2) AND TBP BOUND TO TRNAU1 PROMOTER
675, d4cfwD2, 0.5495, 2.73, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
676, d2c5xD2, 0.5494, 2.74, 0.118, 123, 93, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
677, d4cxaB2, 0.5493, 2.65, 0.141, 129, 92, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
678, d2wfyD2, 0.5493, 2.74, 0.118, 123, 93, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
679, d1urcD2, 0.5493, 2.94, 0.147, 107, 95, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
680, d2uueD2, 0.5492, 2.73, 0.118, 123, 93, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
681, d2iw6D2, 0.5492, 2.73, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
682, d2c5tB2, 0.5492, 2.48, 0.154, 103, 91,  
683, p4cfvD1, 0.5490, 2.73, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
684, d1h26D2, 0.5490, 2.71, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
685, d2uueB2, 0.5489, 2.73, 0.118, 123, 93, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
686, d2wpaD2, 0.5488, 2.73, 0.118, 123, 93, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
687, d2c5oB2, 0.5488, 2.74, 0.118, 123, 93, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
688, d1h28B2, 0.5488, 2.74, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
689, d5nevD2, 0.5487, 2.74, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
690, d2c5vB2, 0.5487, 2.74, 0.118, 123, 93, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
691, d1vywD2, 0.5487, 2.73, 0.118, 123, 93, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
692, d1okwD2, 0.5487, 2.87, 0.117, 122, 94, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
693, d1okuD4, 0.5487, 2.73, 0.118, 123, 93,  
694, d4eonB2, 0.5486, 2.74, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
695, d1okwB2, 0.5486, 2.73, 0.118, 123, 93, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
696, p5lqeD1, 0.5485, 2.73, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
697, d2wihD2, 0.5485, 2.66, 0.138, 154, 94, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
698, d2c5vD2, 0.5485, 2.75, 0.118, 123, 93, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
699, d1okuB4, 0.5485, 2.74, 0.118, 123, 93,  
700, d1oiyD2, 0.5485, 2.73, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
701, d2wevB2, 0.5484, 2.73, 0.118, 123, 93, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
702, d2c5xB2, 0.5483, 2.73, 0.118, 123, 93, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
703, d1ol1D2, 0.5483, 2.75, 0.129, 122, 93, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
704, p3qhrB1, 0.5481, 2.68, 0.120, 122, 92, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
705, p3m03B_, 0.5481, 2.73, 0.118, 123, 93, CRYSTAL STRUCTURE OF HUMAN ORC6 FRAGMENT
706, d2c5pB4, 0.5481, 2.74, 0.118, 120, 93,  
707, p4cfuB1, 0.5480, 2.67, 0.152, 99, 92, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
708, d2wfyB2, 0.5480, 2.75, 0.118, 123, 93, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
709, d1oi9D2, 0.5480, 2.75, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
710, p5lqeB1, 0.5479, 2.73, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
711, p4cfvB1, 0.5479, 2.66, 0.149, 155, 94, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
712, d2whbB2, 0.5479, 2.75, 0.118, 123, 93, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
713, p4cfuD1, 0.5477, 2.74, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
714, p3qhwB1, 0.5476, 2.90, 0.094, 108, 96, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
715, p3qhrD1, 0.5476, 2.75, 0.118, 123, 93, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
716, d1h1qD2, 0.5475, 2.74, 0.118, 123, 93, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
717, p5hq0B1, 0.5473, 2.75, 0.118, 123, 93, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
718, p4y72B1, 0.5473, 2.79, 0.118, 123, 93, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
719, p2wmbD1, 0.5473, 2.74, 0.118, 123, 93, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
720, p3qhwD1, 0.5471, 2.70, 0.130, 122, 92, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
721, p4yc3B1, 0.5470, 2.75, 0.118, 123, 93, CDK1/CYCLINB1/CKS2 APO
722, p4rocA2, 0.5470, 2.75, 0.118, 123, 93, HUMAN TFIIB-RELATED FACTOR 2 (BRF2) AND TBP BOUND TO U6#2 PROMOTER
723, d1h25D2, 0.5470, 2.74, 0.118, 123, 93, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
724, d1e9hD2, 0.5470, 2.74, 0.118, 123, 93, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
725, d5acbB2, 0.5467, 2.74, 0.118, 123, 93, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
726, d1kxuA2, 0.5461, 2.76, 0.118, 120, 93, CYCLIN H A POSITIVE REGULATORY SUBUNIT OF CDK ACTIVATING KINASE
727, p4cfxD1, 0.5459, 2.74, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
728, p4cfxB1, 0.5459, 2.74, 0.118, 123, 93, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
729, p5n9gF2, 0.5454, 2.76, 0.118, 123, 93, TFIIIB -TBP/BRF2/DNA AND SANT DOMAIN OF BDP1-
730, d4bcqD2, 0.5452, 2.75, 0.118, 123, 93, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
731, p3eocB1, 0.5452, 2.77, 0.118, 123, 93, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
732, p5n9gA2, 0.5449, 2.74, 0.118, 123, 93, TFIIIB -TBP/BRF2/DNA AND SANT DOMAIN OF BDP1-
733, p2wmbB1, 0.5449, 2.83, 0.108, 121, 93, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
734, d1jstD2, 0.5443, 2.74, 0.118, 122, 93, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
735, p2x1nB1, 0.5438, 2.75, 0.118, 123, 93, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
736, p5svac2, 0.5434, 2.75, 0.118, 123, 93, MEDIATOR-RNA POLYMERASE II PRE-INITIATION COMPLEX
737, p4v1oM3, 0.5434, 2.82, 0.118, 123, 93, ARCHITECTURE OF THE RNA POLYMERASE II-MEDIATOR CORE TRANSCRIPTION INITIATION COMPLEX
738, p4v1nM3, 0.5434, 2.74, 0.118, 123, 93, ARCHITECTURE OF THE RNA POLYMERASE II-MEDIATOR CORE TRANSCRIPTION INITIATION COMPLEX
739, p4bbsM2, 0.5434, 2.75, 0.118, 123, 93, STRUCTURE OF AN INITIALLY TRANSCRIBING RNA POLYMERASE II- TFIIB COMPLEX
740, p2x1nD1, 0.5434, 2.76, 0.118, 123, 93, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
741, p2wmaB1, 0.5431, 2.70, 0.130, 122, 92, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
742, p3eocD1, 0.5430, 2.50, 0.156, 95, 90, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
743, p2w2hA1, 0.5425, 2.50, 0.156, 95, 90, STRUCTURAL BASIS OF TRANSCRIPTION ACTIVATION BY THE CYCLIN T1-TAT-TAR RNA COMPLEX FROM EIAV
744, d4nstB2, 0.5408, 2.74, 0.118, 123, 93, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
745, p5n61Q3, 0.5407, 2.70, 0.130, 122, 92, RNA POLYMERASE I INITIALLY TRANSCRIBING COMPLEX
746, d1jkwA2, 0.5405, 2.76, 0.118, 123, 93, STRUCTURE OF CYCLIN MCS2
747, p5lqfE1, 0.5393, 2.78, 0.118, 121, 93, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
748, p2jgzB1, 0.5385, 2.83, 0.108, 121, 93, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
749, p1zp2A2, 0.5364, 2.70, 0.130, 122, 92, STRUCTURE OF THE MEDIATOR SUBUNIT CYCLIN C
750, d4cxaD2, 0.5359, 2.76, 0.118, 123, 93, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
751, p5zr1F_, 0.5355, 2.72, 0.130, 122, 92, SACCHAROMYCES CEREVISIAE ORIGIN RECOGNITION COMPLEX BOUND TO A 72-BP ORIGIN DNA CONTAINING ACS AND B1 ELEMENT 
752, p5oa1U2, 0.5355, 2.71, 0.130, 122, 92, RNA POLYMERASE I PRE-INITIATION COMPLEX
753, p5w65P3, 0.5341, 2.70, 0.130, 122, 92, RNA POLYMERASE I INITIAL TRANSCRIBING COMPLEX STATE 2
754, d5efqB2, 0.5337, 2.75, 0.118, 123, 93, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
755, d5acbA2, 0.5334, 2.67, 0.141, 129, 92, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
756, p3m03A_, 0.5329, 2.67, 0.141, 129, 92, CRYSTAL STRUCTURE OF HUMAN ORC6 FRAGMENT
757, d2phgA2, 0.5326, 2.69, 0.120, 122, 92, MODEL FOR VP16 BINDING TO TFIIB
758, p4eljA1, 0.5317, 2.72, 0.130, 122, 92, CRYSTAL STRUCTURE OF THE INACTIVE RETINOBLASTOMA PROTEIN PHOSPHORYLATED AT T373
759, d4nstD2, 0.5315, 2.70, 0.141, 130, 92, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
760, d1f5qB2, 0.5307, 2.67, 0.149, 154, 94, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
761, p2w2hB1, 0.5306, 2.78, 0.118, 123, 93, STRUCTURAL BASIS OF TRANSCRIPTION ACTIVATION BY THE CYCLIN T1-TAT-TAR RNA COMPLEX FROM EIAV
762, p6b3eD2, 0.5303, 2.78, 0.118, 123, 93, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
763, p6eu0Z3, 0.5297, 3.06, 0.092, 110, 98, RNA POLYMERASE III OPEN PRE-INITIATION COMPLEX (OC-PIC)
764, d4un0B2, 0.5297, 2.91, 0.117, 125, 94, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
765, d5efqD2, 0.5296, 2.86, 0.129, 122, 93, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
766, d4cjyB2, 0.5291, 2.75, 0.120, 122, 92,  
767, d4cjyA2, 0.5290, 2.65, 0.149, 153, 94,  
768, d4un0A2, 0.5285, 2.90, 0.118, 121, 93, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
769, d2i53A2, 0.5274, 2.74, 0.120, 122, 92, CRYSTAL STRUCTURE OF CYCLIN K
770, p5w66P3, 0.5272, 2.65, 0.149, 160, 94, RNA POLYMERASE I INITIAL TRANSCRIBING COMPLEX STATE 3
771, d1f5qD2, 0.5269, 2.65, 0.149, 160, 94, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
772, p6f42V3, 0.5265, 2.73, 0.120, 122, 92, RNA POLYMERASE III CLOSED COMPLEX CC1.
773, p5w64P3, 0.5265, 2.78, 0.118, 123, 93, RNA POLYMERASE I INITIAL TRANSCRIBING COMPLEX STATE 1
774, p6f40V3, 0.5248, 2.74, 0.120, 122, 92, RNA POLYMERASE III OPEN COMPLEX
775, p3k7aM2, 0.5238, 1.99, 0.083, 85, 84, CRYSTAL STRUCTURE OF AN RNA POLYMERASE II-TFIIB COMPLEX
776, p6b3eB2, 0.5204, 1.99, 0.083, 86, 84, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
777, p3m03C_, 0.5191, 1.99, 0.083, 86, 84, CRYSTAL STRUCTURE OF HUMAN ORC6 FRAGMENT
778, d1tfbA2, 0.5167, 1.99, 0.083, 85, 84, NMR STUDIES OF HUMAN GENERAL TRANSCRIPTION FACTOR TFIIB: DYNAMICS AND INTERACTION WITH VP16 ACTIVATION DOMAIN 20 STRUCTURES
779, p3h4cA2, 0.5115, 2.75, 0.120, 122, 92, STRUCTURE OF THE C-TERMINAL DOMAIN OF TRANSCRIPTION FACTOR IIB FROM TRYPANOSOMA BRUCEI
780, p6f44V4, 0.5112, 2.74, 0.120, 122, 92, RNA POLYMERASE III CLOSED COMPLEX CC2.
781, d1w98B1, 0.5107, 2.75, 0.120, 122, 92, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
782, d5l2wB2, 0.5095, 3.06, 0.149, 106, 94, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
783, p6f41V3, 0.5091, 2.95, 0.094, 108, 96, RNA POLYMERASE III INITIALLY TRANSCRIBING COMPLEX
784, p2qdjA1, 0.5041, 2.85, 0.100, 147, 90, CRYSTAL STRUCTURE OF THE RETINOBLASTOMA PROTEIN N-DOMAIN PROVIDES INSIGHT INTO TUMOR SUPPRESSION LIGAND INTERACTION AND HOLOPROTEIN ARCHITECTURE
785, p5w5yP3, 0.5001, 2.99, 0.117, 126, 94, RNA POLYMERASE I INITIAL TRANSCRIBING COMPLEX
